Key takeaways
- Whether a GHK-Cu product is a cosmetic or a drug “is determined by a product’s intended use”, FDA says, and intended use can be shown by labeling, advertising, “the design or composition of the article” and how it is distributed.
- Drugs@FDA lists no drug containing GHK-Cu, copper tripeptide or prezatide, and GHK-Cu is not on the 503A bulks list in 21 CFR 216.23 or in HHS’s October 2026 peptide policy; FDA lists it, except for injectable routes, in Category 1, bulk substances under evaluation (18 Nov 2026).
- FDA’s compounding page lists injectable GHK-Cu among withdrawn Category 2 nominations and says compounded injectable drugs containing it “may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities”.
- FDA says its compounding advisory committee will discuss GHK-Cu for the 503A bulks list at a meeting before the end of February 2027, with no date announced by 18 November 2026; FDA describes such committees as making “non-binding recommendations”.
- FDA’s enforcement data list three firm-initiated Class II recalls of GHK-Cu products, started in 2020, 2025 and 2026, citing lack of sterility assurance or of processing controls.
01How does US law classify GHK-Cu?
We found no US law that lists GHK-Cu by name. Under the Federal Food, Drug, and Cosmetic Act, the same ingredient can be part of a cosmetic or of a drug, and FDA says which one “is determined by a product’s intended use”.
Cosmetic. The Act defines cosmetics as “articles intended to be rubbed, poured, sprinkled, or sprayed on, introduced into, or otherwise applied to the human body...for cleansing, beautifying, promoting attractiveness, or altering the appearance” (section 201(i)). GHK-Cu’s cosmetic ingredient name is copper tripeptide-1. FDA says “cosmetic products and ingredients, with the exception of color additives, do not require FDA approval before they go on the market”. Since the Modernization of Cosmetics Regulation Act of 2022, cosmetic facilities register with FDA, each marketed product is listed with its ingredients, and the responsible person must report serious adverse events to FDA within 15 business days.
Drug. The Act also defines drugs by intended use, including “articles (other than food) intended to affect the structure or any function of the body of man or other animals” (section 201(g)(1)). FDA gives examples of claims that make a product a drug even when it is sold as a cosmetic, among them claims that it will “regenerate cells”. A product with both uses must meet both sets of rules.
How intended use is shown. FDA’s regulation defines intended use as “the objective intent of the persons legally responsible for the labeling”, and says “the intent may be shown by such persons’ expressions, the design or composition of the article, or by the circumstances surrounding the distribution of the article” (21 CFR 201.128). FDA’s cosmetics page adds consumer perception and ingredients with a well-known therapeutic use. The wider rules: peptides and US law and peptides in skincare.
02Is GHK-Cu an approved drug in the US?
We found no approved drug containing it. Drugs@FDA, queried through openFDA for the active ingredients “prezatide”, “copper tripeptide” and “GHK”, returned no matches on 18 November 2026. FDA says drugs must generally either receive premarket approval through a new drug application or conform to an over-the-counter monograph.
Compounding. A state-licensed pharmacy compounding under section 503A must use bulk ingredients that meet a USP or NF monograph, belong to an FDA-approved drug, or appear on the 503A bulks list. GHK-Cu is not on that list: 21 CFR 216.23(a) does not name it (eCFR, version of 16 November 2026). FDA’s interim policy also covers substances still under evaluation. Its list of nominated substances, updated 14 May 2026, places “GHK-Cu (except for injectable routes of administration)” in Category 1, “bulk drug substances under evaluation”, and FDA says it “does not intend to take action against a compounder for compounding drugs using bulk drug substances listed in category 1, provided that the conditions described in the guidance document are met”. The injectable route is not in Category 1 (next section). Nor is GHK-Cu one of the six peptides in HHS’s October 2026 enforcement-discretion policy, which covers BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500: the HHS policy explained.
Controlled substances. GHK-Cu does not appear in the federal controlled-substance schedules, 21 CFR Part 1308 (eCFR, 16 November 2026). For GHK-Cu the live questions are drug and cosmetic law, not drug scheduling.
03What has FDA said about compounded GHK-Cu?
FDA’s page on bulk drug substances that may present significant safety risks lists “GHK-Cu (for injectable routes of administration)” in its table of substances “previously in category 2” whose nominations “were withdrawn by the nominators”. The entry reads: “Compounded injectable drugs containing GHK-Cu may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities. There are limited data in humans to inform safety-related considerations.” Immunogenicity is the tendency to provoke an immune response. The page is current as of 22 April 2026. FDA’s list of nominated substances gives that date for removing GHK-Cu from Category 1 after its nominations were withdrawn, and records that on 5 May 2026 one nominator said it had meant to withdraw only the injectable route; FDA then put GHK-Cu, except for injectable routes, back in Category 1. How the categories work: FDA peptide categories.
FDA’s advisory committee page says FDA “will host an advisory committee meeting before the end of February 2027”, at which its Pharmacy Compounding Advisory Committee will discuss five bulk drug substances “being considered for inclusion on the 503A bulks list”: cathelicidin (LL-37), GHK-Cu, dihexa acetate, melanotan II and pegylated mechano growth factor (PEG-MGF). The page is current as of 15 April 2026. FDA says it intends to publish a Federal Register notice for the meeting; none had appeared when we searched on 18 November 2026, and the page says the meeting’s time and location “will be scheduled in the coming months”. FDA describes advisory committees as making “non-binding recommendations”.
GHK-Cu was not on the agenda of the committee’s July 2026 meeting, which covered seven peptides: what the July 2026 panel decided.
04What recalls and warning letters name GHK-Cu?
FDA’s enforcement reports, as published through openFDA (data updated 11 November 2026), list three recalls of GHK-Cu products. Each was voluntary, started by the firm, and classified by FDA as Class II, which FDA defines as “a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote”.
| Recall | Started by the firm | Classified by FDA | Product, as FDA describes it | Reason given |
|---|---|---|---|---|
| D-0141-2021 | 30 Nov 2020 | 11 Dec 2020, Class II | A GHK-Cu vial from an Indiana firm | “Lack of Assurance of Sterility: due to concerns with production processes which cannot assure sterility of products intended to be sterile.” |
| D-0051-2026 | 30 Jul 2025 | 21 Oct 2025, Class II | “GHK-Cu (Copper Peptide) for Injection, all strengths and presentations”, from a Florida firm that recalled many other products at the same time | “Lack of Assurance of Sterility” |
| D-0129-2027 | 19 Oct 2026 | 30 Oct 2026, Class II | A GHK-Cu vial from a Texas pharmacy | “Lack of Processing Controls” |
These records concern particular products and lots, and the reasons FDA gives are about manufacturing and sterility assurance.
Warning letters. FDA sent warning letters to online peptide sellers in 2025 and 2026. The eight we read, dated 12 December 2025 to 24 August 2026, do not mention GHK-Cu. FDA’s 2026 letters treated peptide products labelled “research use only” as unapproved new drugs where the seller’s website showed they were meant for people: what “research use only” means.
05What changed for GHK-Cu in 2026?
The US steps that name GHK-Cu or bear on it, in order.
| Date | What happened | Source |
|---|---|---|
| 15 Apr 2026 | FDA publishes its committee page naming GHK-Cu among five substances its compounding advisory committee will discuss, at a meeting before the end of February 2027 | FDA committee page |
| 22 Apr 2026 | FDA removes GHK-Cu from Category 1 after its nominations are withdrawn; its safety-risk page lists injectable GHK-Cu among withdrawn Category 2 nominations | FDA category list; FDA compounding page |
| 14 May 2026 | FDA puts GHK-Cu, except for injectable routes, back in Category 1, substances under evaluation, after one nominator said on 5 May that it had meant to withdraw only the injectable route | FDA category list |
| 23–24 Jul 2026 | The committee meets on seven peptides; GHK-Cu is not on that agenda | FDA meeting record |
| 24 Aug 2026 | FDA warning letters to four online peptide sellers; none mentions GHK-Cu | FDA warning letters |
| 28–30 Oct 2026 | HHS enforcement-discretion policy for six peptides, published in the Federal Register on 30 October; GHK-Cu is not among them | HHS; Federal Register |
| 30 Oct 2026 | FDA classifies the third GHK-Cu recall (D-0129-2027) | openFDA enforcement data |
| 18 Nov 2026 | No Federal Register notice yet for the 2027 committee meeting | Federal Register search |
| By end Feb 2027 | Committee meeting due, with GHK-Cu on the agenda | FDA committee page |
Every change is logged in our regulatory changelog.
06How is GHK-Cu treated in sport?
US drug and cosmetic law has no bearing on anti-doping rules. WADA’s Prohibited List does not name GHK-Cu, in the 2026 List or in the 2027 List that takes effect on 1 January 2027. Class S0 covers pharmacological substances with “no current approval by any governmental regulatory health authority for human therapeutic use”, and anti-doping organisations decide how it applies; WADA’s notes on the 2027 List say a peptide not specifically named “may still be prohibited”. The US Anti-Doping Agency is one of the agencies behind Global DRO, which gives information on medications against the current List. More: peptides and anti-doping.
07What we don’t know about GHK-Cu in the US
- What the advisory committee will recommend, when exactly it will meet, and whether FDA will propose adding GHK-Cu to the 503A bulks list. No Federal Register notice had appeared by 18 November 2026.
- How FDA would classify a particular GHK-Cu product. It turns on intended use, judged product by product.
- Whether FDA has sent a warning letter that names GHK-Cu. The letters we read do not, and FDA’s letter database is not fully searchable by our tools.
- State rules. State boards license prescribers and pharmacies; we have not found a state action that names GHK-Cu.
- How compounded injectable GHK-Cu behaves in people. FDA cites “limited data in humans”: GHK-Cu side effects.
The compound itself: the GHK-Cu research guide.
This is a plain-English summary of public documents, checked on 18 Nov 2026. It is not legal advice.